Trial · NCT02469090
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Mean Change From Pre-Dose to 30 Minutes Post-Dose in The Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS Part III) Score at Maintenance Visit 4 (MV4) - Week 12 | Placebo (Maintenance) | -3.5 | Standard Error 1.29 | Units on a scale | |
Mean Change From Pre-Dose to 30 Minutes Post-Dose in The Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS Part III) Score at Maintenance Visit 4 (MV4) - Week 12 | APL-130277 (Maintenance) | -11.1 | Standard Error 1.46 | Units on a scale | |
| Percentage of Patients With a Patient-related Full 'ON' Response Within 30 Minutes at MV4 - Week 12: Predicted Response Rate | Placebo (Maintenance) | 16 | number of participants | ||
| Percentage of Patients With a Patient-related Full 'ON' Response Within 30 Minutes at MV4 - Week 12: Predicted Response Rate | APL-130277 (Maintenance) | 35 | number of participants | ||
| Percentage of Patients With a Patient-related Full 'ON' Response Within 30 Minutes That Had a Duration of Effect of at Least 30 Minutes at MV4 - Week 12: Predicted Response Rate | Placebo (Maintenance) | 14 | number of participants | ||
| Percentage of Patients With a Patient-related Full 'ON' Response Within 30 Minutes That Had a Duration of Effect of at Least 30 Minutes at MV4 - Week 12: Predicted Response Rate | APL-130277 (Maintenance) | 31 | number of participants | ||
| Patient Global Impression of Improvement (PGI-I): Percentage of Patients Who Improved at MV4 - Week 12 | Placebo (Maintenance) | 20.0 | percentage of participants | ||
| Patient Global Impression of Improvement (PGI-I): Percentage of Patients Who Improved at MV4 - Week 12 | APL-130277 (Maintenance) | 37.0 | percentage of participants | ||
| Clinician Global Impression of Improvement (CGI-I): Percentage of Patients Who Improved at MV4 - Week 12 | Placebo (Maintenance) | 20.0 | percentage of participants | ||
| Clinician Global Impression of Improvement (CGI-I): Percentage of Patients Who Improved at MV4 - Week 12 | APL-130277 (Maintenance) | 40.7 | percentage of participants | ||
| Mean Change From Screening Visit to MV4 (Week 12) in MDS-UPDRS Part II: Motor Aspects of Experience of Daily Living | Placebo (Maintenance) | 2.095 | 95% Confidence Interval 0.749 to 3.440 | units on a scale | |
| Mean Change From Screening Visit to MV4 (Week 12) in MDS-UPDRS Part II: Motor Aspects of Experience of Daily Living | APL-130277 (Maintenance) | 0.995 | 95% Confidence Interval -0.559 to 2.549 | units on a scale | |
| Mean Percentage of Instances Where a Full 'ON' Response Was Achieved at 30 Minutes Post-dose on the Home Dosing Diary Entries During the 2 Days Prior to MV4 - Week 12 | Placebo (Maintenance) | 31.10 | 95% Confidence Interval 19.25 to 42.95 | percentage of instnces | |
| Mean Percentage of Instances Where a Full 'ON' Response Was Achieved at 30 Minutes Post-dose on the Home Dosing Diary Entries During the 2 Days Prior to MV4 - Week 12 | APL-130277 (Maintenance) | 78.70 | 95% Confidence Interval 64.16 to 93.24 | percentage of instnces | |
| Mean Change From Screening Visit to MV4 in the Parkinson's Disease Quality of Life Questionnaire (PDQ-39) Summary Index Score | Placebo (Maintenance) | -1.671 | 95% Confidence Interval -4.442 to 1.101 | units on a scale | |
| Mean Change From Screening Visit to MV4 in the Parkinson's Disease Quality of Life Questionnaire (PDQ-39) Summary Index Score | APL-130277 (Maintenance) | 0.309 | 95% Confidence Interval -2.748 to 3.366 | units on a scale | |
| Mean Change From Pre-Dose to 15 Minutes Post-Dose in the MDS-UPDRS Part III Score at MV4 - Week 12 | Placebo (Maintenance) | -3.0 | 95% Confidence Interval -5.1 to -0.8 | units on a scale | |
| Mean Change From Pre-Dose to 15 Minutes Post-Dose in the MDS-UPDRS Part III Score at MV4 - Week 12 | APL-130277 (Maintenance) | -6.4 | 95% Confidence Interval -8.8 to -4.0 | units on a scale | |
| Time From Dosing to When Study Medication Provided an Effect at MV4 - Week 12 | Placebo (Maintenance) | NA | 95% Confidence Interval 42.73 to NA | Minutes | |
| Time From Dosing to When Study Medication Provided an Effect at MV4 - Week 12 | APL-130277 (Maintenance) | 21.2 | 95% Confidence Interval 15.00 to 27.00 | Minutes |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02469090/results